Immune checkpoint inhibitors or docetaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsmall Cell Lung Cancer
Conditions
Nonsmall Cell Lung Cancer, NSCLC
Trial Timeline
Dec 1, 2016 → Oct 9, 2024
NCT ID
NCT02973789About Immune checkpoint inhibitors or docetaxel
Immune checkpoint inhibitors or docetaxel is a phase 3 stage product being developed by Novocure for Nonsmall Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02973789. Target conditions include Nonsmall Cell Lung Cancer, NSCLC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02973789 | Phase 3 | Completed |
Competing Products
7 competing products in Nonsmall Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apatinib combined with pemetrexed | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Cisplatin + Carboplatin | AbbVie | Pre-clinical | 23 |
| SLC-391 + pembrolizumab | Merck | Phase 1/2 | 41 |
| Erlotinib | Roche | Pre-clinical | 23 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Pemetrexed + Carboplatin + demcizumab | Mereo BioPharma | Phase 2 | 44 |